PRPH vs. CGTX, FNCH, ALLK, LVTX, PLUR, LSB, ENLV, DRRX, COCP, and CTXR
Should you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include Cognition Therapeutics (CGTX), Finch Therapeutics Group (FNCH), Allakos (ALLK), LAVA Therapeutics (LVTX), Pluri (PLUR), Lakeshore Biopharma (LSB), Enlivex Therapeutics (ENLV), DURECT (DRRX), Cocrystal Pharma (COCP), and Citius Pharmaceuticals (CTXR). These companies are all part of the "pharmaceutical products" industry.
ProPhase Labs vs.
Cognition Therapeutics (NASDAQ:CGTX) and ProPhase Labs (NASDAQ:PRPH) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment.
43.4% of Cognition Therapeutics shares are owned by institutional investors. Comparatively, 9.5% of ProPhase Labs shares are owned by institutional investors. 20.8% of Cognition Therapeutics shares are owned by company insiders. Comparatively, 20.7% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
ProPhase Labs received 93 more outperform votes than Cognition Therapeutics when rated by MarketBeat users. However, 70.00% of users gave Cognition Therapeutics an outperform vote while only 49.14% of users gave ProPhase Labs an outperform vote.
ProPhase Labs has higher revenue and earnings than Cognition Therapeutics. Cognition Therapeutics is trading at a lower price-to-earnings ratio than ProPhase Labs, indicating that it is currently the more affordable of the two stocks.
Cognition Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. ProPhase Labs' return on equity of -62.92% beat Cognition Therapeutics' return on equity.
In the previous week, ProPhase Labs had 7 more articles in the media than Cognition Therapeutics. MarketBeat recorded 9 mentions for ProPhase Labs and 2 mentions for Cognition Therapeutics. Cognition Therapeutics' average media sentiment score of 0.00 beat ProPhase Labs' score of -0.37 indicating that Cognition Therapeutics is being referred to more favorably in the media.
Cognition Therapeutics currently has a consensus target price of $8.30, suggesting a potential upside of 1,323.18%. Given Cognition Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Cognition Therapeutics is more favorable than ProPhase Labs.
Cognition Therapeutics has a beta of 0.96, suggesting that its share price is 4% less volatile than the S&P 500. Comparatively, ProPhase Labs has a beta of -0.37, suggesting that its share price is 137% less volatile than the S&P 500.
Summary
Cognition Therapeutics beats ProPhase Labs on 11 of the 18 factors compared between the two stocks.
Get ProPhase Labs News Delivered to You Automatically
Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
ProPhase Labs Competitors List
Related Companies and Tools
This page (NASDAQ:PRPH) was last updated on 2/22/2025 by MarketBeat.com Staff
Free PRPH Stock Alerts